Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma.

被引：0
|
作者：
Ran, Tao
Medhekar, Rohan
Fu, Alex Z.
Patel, Sharmila
Kaila, Shuchita
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] Georgetown Univ, Med Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8039
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Maclachlan, Kylee
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Usmani, Saad
    Lesokhin, Alexander
    Korde, Neha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
  • [32] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [33] Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
    Rajkumar, SV
    Hayman, S
    Lacy, MQ
    Dispenzieri, A
    Geyer, SM
    Kabat, B
    Zeldenrust, SR
    Kumar, S
    Greipp, PR
    Fonseca, R
    Lust, JA
    Russell, SJ
    Kyle, RA
    Witzig, TE
    Gertz, MA
    BLOOD, 2005, 106 (11) : 230A - 231A
  • [34] Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Phuong-Dung, Liang
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Malave, Gabriella C.
    Vossen, Alanna M.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    BLOOD, 2020, 136
  • [35] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Ajay K. Nooka
    Jonathan L. Kaufman
    Cesar Rodriguez
    Andrzej Jakubowiak
    Yvonne Efebera
    Brandi Reeves
    Tanya Wildes
    Sarah A. Holstein
    Larry D. Anderson
    Ashraf Badros
    Leyla Shune
    Ajai Chari
    Huiling Pei
    Annelore Cortoos
    Sharmila Patel
    J. Blake Bartlett
    Jessica Vermeulen
    Thomas S. Lin
    Paul G. Richardson
    Peter Voorhees
    Blood Cancer Journal, 12
  • [36] Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma
    Ghosh, Nilanjan
    Ye, Xiaobu
    Ferguson, Anna
    Huff, Carol Ann
    Borrello, Ivan
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (05) : 593 - 599
  • [37] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [38] Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma
    Ghosh, Nilanjan
    Ferguson, Anna
    Ye, Xiaobu
    Huff, Carol A.
    Borrello, Ivan M.
    BLOOD, 2009, 114 (22) : 1119 - 1119
  • [39] Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
    Richardson, Paul G.
    Durie, Brian G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Dispenzieri, Angela
    Moreau, Philippe
    Kumar, Shaji
    Raje, Noopur
    Munshi, Nikhil
    Laubach, Jacob P.
    O'Gorman, Peter
    O'Donnell, Elizabeth
    Voorhees, Peter
    Facon, Thierry
    Blade, Joan
    Lonial, Sagar
    Perrot, Aurore
    Anderson, Kenneth C.
    HAEMATOLOGICA, 2023, 108 (11) : 2894 - 2912
  • [40] Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
    Narsipur, Nihal
    Bulla, Sabrina
    Yoo, Connie
    Do, Brenda
    Tran, Kyle
    Gu, Dian
    Zhong, Lixian
    Wilson, Leslie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (12): : 1691 - 1702
12345